Parnax Lab Ltd. has submitted its mandatory quarterly compliance certificate to the Bombay Stock Exchange (BSE) for the quarter ended March 31, 2026, confirming regulatory adherence under SEBI (Depositories and Participants) Regulations, 2018.

Quarterly Compliance Filing Details

The pharmaceutical company filed the confirmation certificate on April 8, 2026, addressing the Department of Corporate Service (DCS-CRD) at BSE. The filing pertains to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which mandates quarterly reporting on dematerialization activities.

Dematerialization Status Confirmation

Parnax Lab confirmed through its registrar and transfer agent, MUFG Intime India Private Limited, that no dematerialization requests were received during the quarter ended March 31, 2026. This confirmation forms the basis of the compliance certificate submitted to the stock exchange.

The certificate was signed by Preet Kukreja, Company Secretary and Compliance Officer (ACS No.: 56761), ensuring proper authorization and compliance with corporate governance requirements.

Registrar Verification Process

MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, serves as the company's registrar and transfer agent. The registrar provided the necessary confirmation regarding the absence of dematerialization requests during the reporting quarter, enabling Parnax Lab to fulfill its regulatory obligations.

Regulatory Compliance Framework

This quarterly filing represents part of the mandatory compliance framework established by SEBI for listed companies. The regulation requires companies to report on dematerialization activities and maintain transparency in share transfer processes. Such filings ensure proper record-keeping and regulatory oversight of securities transactions in the Indian capital markets.

Parnax Lab Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, following approval by the Board of Directors at their meeting held on February 13, 2026. The pharmaceutical company demonstrated strong operational performance across both standalone and consolidated operations during the third quarter of fiscal year 2026.

Board Meeting and Regulatory Compliance

The Board of Directors meeting commenced at 4:00 PM and concluded at 4:30 PM on February 13, 2026, at the company's registered office. The meeting considered and approved the standalone and consolidated unaudited financial results pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. C.N. Patel & Co., Chartered Accountants, conducted a limited review of both standalone and consolidated financial results.

Consolidated Financial Performance

The company's consolidated operations showed robust growth momentum during Q3FY26. Revenue from operations reached ₹6,294.15 lakhs, representing a substantial 56.45% increase from ₹4,021.61 lakhs recorded in the corresponding quarter of the previous year. Total revenue, including other income, stood at ₹6,391.30 lakhs compared to ₹4,040.56 lakhs in Q3FY25.

Net profit after minority interest surged 124.29% to ₹271.47 lakhs in Q3FY26 from ₹121.02 lakhs in the same quarter last year. The company's earnings per share (basic) improved significantly to ₹2.37 from ₹1.06, reflecting the strong bottom-line performance.

Nine-Month Consolidated Results

For the nine months ended December 31, 2025, consolidated revenue from operations grew 29.01% to ₹17,891.89 lakhs compared to ₹13,869.93 lakhs in the corresponding period of the previous year. Net profit for the nine-month period increased 11.65% to ₹960.03 lakhs from ₹859.92 lakhs, demonstrating consistent profitability growth.

Standalone Financial Performance

The standalone operations also exhibited strong growth with revenue from operations reaching ₹270.82 lakhs in Q3FY26, marking a remarkable 174.58% increase from ₹98.63 lakhs in Q3FY25. Net profit for the quarter surged 349.43% to ₹70.91 lakhs compared to ₹15.78 lakhs in the previous year's corresponding quarter.

For the nine-month period, standalone revenue grew modestly by 3.15% to ₹637.68 lakhs, while net profit declined 2.76% to ₹143.74 lakhs from ₹147.82 lakhs in the previous year.

Exceptional Items and Labour Code Impact

The company reported exceptional expenses of ₹113.80 lakhs in consolidated results and ₹2.16 lakhs in standalone results for Q3FY26. These exceptional items primarily relate to incremental gratuity impact arising from changes in wage definition following the Government of India's notification of four Labour Codes on November 21, 2025. The consolidated tax expense for Q3FY26 totaled ₹53.29 lakhs, comprising current tax of ₹60.60 lakhs and deferred tax benefit of ₹7.31 lakhs.

Corporate Information

Parnax Lab Limited operates primarily in the pharmaceutical formulations segment and maintains a paid-up equity share capital of ₹1,148.56 lakhs with a face value of ₹10 per share. The company continues to focus on strengthening its market position through operational excellence and strategic growth initiatives.